• Home
  • Prostate cancer hormone (GnRH) injections

Prostate cancer hormone (GnRH) injections

NCL Wide
Under Review — this page was due to be reviewed by Sunday, 12 May 2024. The information shown here may be outdated.

Gonadotropin Releasing Hormone (GnRH) analogue injections, also known as Luteinising Hormone Releasing Hormone (LHRH) injections, are indicated for treatment of men with prostate cancer.

In January 2022, the service model for ongoing prescribing and administration of GnRH analogues in NCL changed.

What changed?

Rather than attending a hospital outpatient clinic for their GnRH analogue injections every three or six months, patients now have their injections administered at a local practice, usually by the practice nurse. This model was phased in over 2022-23.

Patients will remain the clinical responsibility of their specialist hospital team, and will be monitored and able to access their specialist nurse or consultant as they were able to previously. The only change is where they receive their GnRH analogue injections.

Why the change?

Prior to this change, around two thirds of patients in NCL were prescribed and administered their GnRH analogue injection in primary care, whereas the remaining third received the injections in hospital.

NCL ICB and the NCL Cancer Alliance is working together to ensure that, where possible, all patients receive care that is equitable, fairer, and provided closer to their home. This model for administering GnRH analogues in NCL is considered best practice and is standard in many other areas across the UK. The NCL enhanced service for GnRH analogue injections for prostate cancer will enable this service model in NCL.


Review date: Sunday, 12 May 2024